Spinal phospholipase A2 in inflammatory hyperalgesia: role of the small, secretory phospholipase A2.
Current work emphasizes that peripheral tissue injury and inflammation results in a heightened sensitivity to subsequent noxious input (hyperalgesia) that is mediated in large part by the spinal synthesis and release of eicosanoids, in particular prostaglandins. Secreted phospholipase A(2)s (sPLA(2)s) form a class of structurally related enzymes that release arachidonic acid from cell membranes that is further processed to produce eicosanoids. We hypothesized that spinal sPLA(2)s may contribute to inflammation-induced hyperalgesia. Spinal cord tissue and cerebrospinal fluid were collected from rats for assessment of sPLA(2) protein expression and sPLA(2) activity. A basal sPLA(2) protein expression and activity was detected in spinal cord homogenate (87+/-17 pmol/min/mg), though no activity could be detected in cisternal cerebrospinal fluid, of naive rats. The sPLA(2) activity did not change in spinal cord tissue or cerebrospinal fluid assessed over 8 h after injection of carrageenan into the hind paw. However, the sPLA(2) activity observed in spinal cord homogenates was suppressed by addition of LY311727, a selective sPLA(2) inhibitor. To determine the role of this spinal sPLA(2) in hyperalgesia, we assessed the effects of lumbar intrathecal (IT) administration of LY311727 in rats with chronic IT catheters in three experimental models of hyperalgesia. IT LY311727 (3-30 microg) dose-dependently prevented intraplantar carrageenan-induced thermal hyperalgesia and formalin-induced flinching, at doses that had no effect on motor function. IT LY311727 also suppressed thermal hyperalgesia induced by IT injection of substance P (30 nmol). Using in vivo spinal microdialysis, we found that IT injection of LY311727 attenuated prostaglandin E(2) release into spinal dialysate otherwise evoked by the IT injection of substance P. Taken together, this work points to a role for constitutive sPLA(2)s in spinal nociceptive processing.
Svensson
C I
CI
Department of Anesthesiology, School of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.
Lucas
K K
KK
Hua
X-Y
XY
Powell
H C
HC
Dennis
E A
EA
Yaksh
T L
TL
D000818:Animals; D015153:Blotting, Western / Q000379:methods; D002351:Carrageenan; D003956:Dialysis / Q000379:methods; D015232:Dinoprostone / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D007839:Functional Laterality; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects; D054501:Group II Phospholipases A2; D006930:Hyperalgesia / Q000188:drug therapy / Q000201:enzymology* / Q000503:physiopathology; D007211:Indoles / Q000494:pharmacology; D007249:Inflammation / Q000139:chemically induced / Q000150:complications / Q000201:enzymology / Q000503:physiopathology*; D007266:Inhibition, Psychological; D008297:Male; D010147:Pain Measurement / Q000187:drug effects / Q000379:methods; D010741:Phospholipases A / Q000378:metabolism*; D054467:Phospholipases A2; D051381:Rats; D017207:Rats, Sprague-Dawley; D011930:Reaction Time / Q000187:drug effects; D013116:Spinal Cord / Q000187:drug effects / Q000201:enzymology*; D013373:Substance P / Q000494:pharmacology; D013997:Time Factors
D007211:Indoles; C095553:LY 311727; D013373:Substance P; D002351:Carrageenan; D010741:Phospholipases A; D054501:Group II Phospholipases A2; D054467:Phospholipases A2; D015232:Dinoprostone